GSK Trading Volume Surges 39.19% to Rank 418th Despite Stock Price Decline

On May 14, 2025, GSK's trading volume reached 2.58 billion, marking a 39.19% increase from the previous day. This surge placed GSK at the 418th position in terms of trading volume for the day. However, despite the high trading volume, GSK's stock price experienced a decline of 0.36%, marking the second consecutive day of losses and a total decrease of 3.08% over the past two days.

GSK has made a significant move in the pharmaceutical industry by acquiring efimosfermin alfa, a late-stage liver disease drug, from Boston Pharmaceuticals for an upfront payment of $1.2 billion. This acquisition is part of GSK's strategy to expand its hepatology portfolio, focusing on addressing steatotic and viral drivers of liver disease. Efimosfermin alfa is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and future development in alcohol-related liver disease (ALD), both forms of steatotic liver disease (SLD).

The acquisition of efimosfermin alfa is highly aligned with GSK's R&D focus on science related to the immune system and further evidence of the company's intent to build on its deep understanding of fibrosis and auto-inflammation to develop precision interventions that stop and reverse disease progression. SLD represents an area of significant unmet medical need affecting approximately 5% of the global population with limited therapeutic options for patients. The acquisition of efimosfermin alfa will significantly expand GSK’s hepatology pipeline and provide the opportunity to develop a new potential best-in-class medicine with a first launch expected in 2029.